United States: Court Offers Insights On When The 271(E)(1) Safe Harbor Applies To The Use Of Patented Technology In Early – And Late -- Drug Development

FDA-regulated firms -- drug, device, biologic or otherwise -- on both sides of the patent aisle concerned with the bounds of the "Safe Harbor" exception to patent infringement under 35 U.S.C. § 271(e)(1) can learn several key lessons from the recent decision in  Isis Pharmaceuticals, Inc. v Santaris Pharma A/S Corp. (hereafter:  "Isis"),  particularly how to properly prove the safe harbor defense once the litigation unfolds and also when the harbor provides shelter from post-approval patent storms.

A Lesson on Proper Safe Harbor Pleading

In Isis, the district court for the Southern District of California held that, if a drug developer establishes a reasonable basis for believing that a "patented invention" will have a "particular biological effect" through a "particular biological process," such a showing would be sufficient, although not the only way, to establish a safe harbor defense to patent infringement under 35 U.S.C. § 271(e)(1) [hereafter:  "271(e)(1)"].  The safe harbor provision in § 271(e)(1) exempts otherwise infringing acts from patent liability when those acts are performed  "solely for uses reasonably related to the development and submission of information under a Federal law which regulates the . . . use . . . of drugs." 

In reaching its holding, the Isis court relied on the Supreme Court's observation in Merck v Integra that otherwise infringing experimentation on the road to regulatory approval comes within the safe harbor "[a]t least where a drug maker has a reasonable basis for believing that a patented compound may work, through a particular biological process, to produce a particular biological effect . . . ."  Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 207 (2005) (emphasis added). 

By way of background, Isis sued Santaris (a Danish corporation not to be confused with Isis's fellow San Diego-based firm Santarus, recently bought by Salix Pharmaceuticals), accusing Santaris of infringing Isis patents to antisense compounds and methods of making the antisense compounds when Santaris contracted to sell antisense drug discovery services and products to four pharmaceutical company customers in the United States.  Santaris moved for summary judgment on its affirmative defense that the alleged acts of infringement fell within the safe harbor provision of 35 U.S.C. § 271. 

The court denied Santaris's summary judgment motion, finding that Santaris failed to provide undisputed evidence of the belief that the Merck I Court found was needed to properly claim the 271(e)(1) safe harbor (see above quote).  Instead, the Isis court stressed that Santaris's supporting declaration by one of its officers provided only a general description of the collaborations between Santaris and its customers.  This, the court found, did not provide any detailed analysis of Santaris's uses of the allegedly infringing compounds, methods and processes to establish they rose to the level of a reasonable belief, as contemplated by Merck I, as to a patented compound's way of achieving a particular biological effect and, thus, failed to show that Santaris fell under the protection of the 271(e)(1) safe harbor. 

The court also cited the Santaris officer's previous statement to the PTO that, "(t)he majority of [Santaris's] collaborators have taken broad licenses to our proprietary LNA platform in order to discover, develop, and commercialize new LNA-based drugs against RNA targets associated with disease," observing that the reference to selling "platform" technology so that another company could develop and discover drug candidates, suggested that Santaris was using its technology for "basic research" not covered under the § 271(e)(1) safe harbor.

In determining the legal boundaries of the safe harbor afforded by 271(e)(1), the Isis court considered in detail the Supreme Court's ruling in Merck v. Integra, and subsequent lower court cases mapping out the contours of the safe harbor The court noted that the Supreme Court appeared to criticize the Federal Circuit's suggestion that early stage research to "identif[y] the best drug candidate to subject to future clinical testing under the FDA process" fell outside the safe harbor, by providing guidance on circumstances in which early research would fall within the safe harbor, saying:

Properly construed, § 271(e)(1) leaves adequate space for experimentation and failure on the road to regulatory approval:  At least where a drugmaker has a reasonable basis for believing that a patented compound may work, through a particularly biological process, to produce a particular physiological effect, and uses the compound in research that, if successful, would be appropriate to include in a submission to the FDA, that use is "reasonably related" to the "development and submission of information under . . . Federal law." Id. at 207 (quoting § 271(e)(1); emphasis added).

Accordingly, the district court held that a showing that a drugmaker has a reasonable basis for believing that a patented invention will have a "particular biological effect" through a "particular biological process" would have been sufficient to establish a safe harbor defense if sufficient evidence to support it had been submitted.  The district court also agreed with defendant Santaris that the Supreme Court's use of "at least" in the passage quoted above means that the facts listed are sufficient, though not necessarily the only ones required, to come within the safe harbor. 

Nevertheless, although accepting some of Santaris's legal arguments, the Isis court cited Santaris's failure to provide undisputed evidence of such knowledge or belief in denying Santaris's summary judgment motion.  The court found instead that fact issues remained as to whether Santaris's collaboration agreements were "reasonably related" to the type of information submitted to the FDA—that is, whether it was "objectively reasonable for a party in [Santaris's] . . . situation to believe that there was a decent prospect that the accused activities would contribute, relatively directly, to the generation of the kinds of information that are likely to be relevant in the processes by which the FDA would decide whether to approve the product in question"  [citing Merck I, 545 U.S. at 200-01 (district court jury instruction)].  Accordingly, the court found that this fact question regarding what was reasonable, should be left to the trier of fact, as is customary for most questions involving a question of what is reasonable. 

Case Also Tackles Safe Harbor's Application to Allegations of Post-Approval Patent Infringement

Another interesting aspect of the decision is the court's harmonization of what were viewed by some commentators as split decisions in Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011) and Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., 686 F.3d 1348 (Fed. Cir. 2012), on the issue of whether 35 U.S.C. § 271(e)(1) can shield post-approval FDA use of a patented technology.  See, e.g., Sebor & Norton, Momenta Seeks Supreme Court Review of Whether Safe-Harbor Applies to Post-Approval Uses of a Drug, available at http://aiplabiotech.wordpress.com/page/2/.

In 2011's Classen, the Federal Circuit panel majority reversed a district court ruling that the defendants' post approval activities, which included reporting adverse vaccine effects to FDA, fell within the § 271(e)(1) safe harbor provision and held instead that the safe harbor is "limited to activities conducted to obtain pre-marketing approval of generic counterparts of patented inventions" and that the "statute does not apply to information that may be routinely reported to the FDA long after marketing approval has been obtained."  Judge Moore dissented, reasoning that the majority's analysis and construction of the safe harbor provision were "contrary to the plain language of the statute and clear Supreme Court guidance" (referencing Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005)), and "[n]owhere does that statute limit the safe harbor to pre-approval uses."

A year later, in 2012, Judge Moore wrote for the panel majority in Momenta, reaching what was viewed by some as a result conflicting with Classen, by holding that Amphastar's use of Momenta's patented process for analyzing drug quality during post-approval manufacture of enoxaparin for commercial sale fell within the safe harbor.  The Federal Circuit panel majority sided with Amphastar, concluding that the language of §271(e)(1) is broad and "unambiguously applies to submissions under any federal law, providing that the law 'regulates the manufacture, use or sale of drugs,'" and is not only directed to activities related to submission for FDA approval, but also to post approval testing.

After reviewing the two decisions, the Isis court found simply that Classen and Momenta "stand[] for the proposition that, regardless of the stage of the regulatory process in which a patented invention is used to obtain information, the information derived from using the patented invention must be 'reasonably related' to the type of information required by FDA at some point during the regulatory process."  Thus, the district court neatly harmonized what at first appeared to be conflicting decisions in Classen and Momenta.

Key Takeaways

  • Where appropriate, draft agreements for drug discovery collaborations in a way that reflects knowledge or a belief of particular biological processes and particular physiological effects for each collaboration compound.
  • During litigation, in order to obtain safe harbor protection, drugmakers seeking safe harbor protection should submit evidence sufficient to establish knowledge of the "particular biological process" and "particular physiological effect" for each collaboration compound. 
  • If using another's patented invention post-approval, be sure to document, ideally prior to use, the relationship between what you are doing and a corresponding legal duty to submit data to FDA.
  • Train key personnel involved in the safe harbor use of patented technology in the proper ways to document such use so that internal records, patent prosecution records,  and regulatory filings are consistent with an appropriate Safe Harbor claim.

This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.

Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.